Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery

Purpose

This clinical trial compares efficacy in postoperative pain management in thoracic surgery between erector spinae block versus liposomal bupivacaine injections.

Condition

  • Lung Cancers

Eligibility

Eligible Ages
Between 18 Years and 90 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Video assisted pulmonary resection, pleurodesis or decortication

Exclusion Criteria

  • Allergy to local anesthetics - Patient undergoing bilateral surgery - Surgery is emergent as deemed by the principal investigator

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
Preoperative Erector Spinae Block (ESB)(Bupivacaine)(Marcaine®)
  • Drug: Erector Spinae (ESP) Block with Bupivacaine (Marcaine®)
    preoperative erector spinae block with bupivacaine (Marcaine®)
  • Drug: Intercostal nerve block
    intraoperative intercostal nerve block with liposomal bupivacaine (Exparel®)
Active Comparator
Intraoperative Intercostal Nerve Block (INB)(Liposomal Bupivacaine)(Exparel®)
  • Drug: Erector Spinae (ESP) Block with Bupivacaine (Marcaine®)
    preoperative erector spinae block with bupivacaine (Marcaine®)
  • Drug: Intercostal nerve block
    intraoperative intercostal nerve block with liposomal bupivacaine (Exparel®)

Recruiting Locations

The George Washington University Hospital
Washington, District of Columbia 20037
Contact:
Eduard Shaykhinurov
2022038960
eshaykhinurov@mfa.gwu.edu

More Details

NCT ID
NCT06810375
Status
Recruiting
Sponsor
George Washington University

Study Contact

Eduard Shaykhinurov, MS
2022038960
eshaykhinurov@mfa.gwu.edu

For help using this page: trialstoday@researchmatch.org or call 855-514-7001

ResearchMatch is funded in part by the National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program, led by the NIH’s National Center for Advancing Translational Sciences (NCATS), grants UL1TR000445 and 1U54RR032646-01, and grant U24TR001579 from NCATS and the National Library of Medicine. The content of this website is solely the responsibility of ResearchMatch and Vanderbilt University and does not necessarily represent the official views of the NIH, NCATS, or NLM.

Vanderbilt University Medical Center